Background
CNS adverse events of marketed anti-malarial drugs
Preclinical evaluations
Clinical adverse events
Neurological disorders |
Peripheral neuropathies, headaches, nervous system neoplasms malignant and unspecified (NEC), spinal cord and nerve root disorders, congenital and peripartum neurological conditions, demyelinating disorders, nervous system neoplasms benign, increased intracranial pressure and hydrocephalus, movement disorders (incl. Parkinsonism), encephalopathies, seizures (incl. subtypes), mental impairment disorders, neurological disorders of the eye, cranial nerve disorders (excl. neoplasms), structural brain disorders, neuromuscular disorders, central nervous system infections and inflammations, sleep disturbances (incl. subtypes), central nervous system vascular disorders |
Psychiatric disorders |
This is currently based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) and includes changes in physical activity, eating disorders and disturbances, impulse control disorders NEC, cognitive and attention disorders and disturbances, dissociative disorders, somatic symptom and related disorders, sleep disorders and disturbances, psychiatric and behavioural symptoms NEC, disturbances in thinking and perception, schizophrenia and other psychotic disorders, adjustment disorders (incl. subtypes), communication disorders and disturbances, sexual dysfunctions, disturbances and gender identity disorders, developmental disorders NEC, suicidal and self-injurious behaviours NEC, dementia and amnestic conditions, deliria (incl. confusion), manic and bipolar mood disorders and disturbances, anxiety disorders and symptoms, mood disorders and disturbances NEC, personality disorders and disturbances in behaviour, depressed mood disorders and disturbances |
Confounding factors in evaluating NPAE risk
Malaria effects versus drug effects in patients
Prophylaxis versus treatment
Underlying neuropsychiatric risk
Tafenoquine pre-clinical neurotoxicity assessment
Tafenoquine for P. vivax relapse prevention
High-dose tafenoquine monotherapy versus chloroquine/primaquine
High-dose tafenoquine/chloroquine
Adverse event, n (%) | Tafenoquine 300 mg q.d. × 7 days (N = 18) | Tafenoquine 600 mg q.d. × 3 days (N = 19) | Tafenoquine 600 mg single dose (N = 18) | Primaquine 15 mg q.d. × 14 days (N = 12) |
---|---|---|---|---|
Any NPAE | 8 (44) | 8 (42) | 4 (22) | 6 (50) |
Vertigo | 8 (44) | 8 (42) | 4 (22) | 3 (25) |
Headache | 4 (22) | 4 (21) | 2 (11) | 4 (33) |
Single-dose tafenoquine/chloroquine
-
DETECTIVE Phase 2b (TAF112582 part 1): a multicentre, phase 2b, double-blind, placebo-controlled, randomized, dose-selection study of single-dose tafenoquine (50, 100, 300, 600 mg) plus standard 3-day chloroquine versus placebo plus standard 3-day chloroquine or primaquine 15 mg for 14 days plus standard 3-day chloroquine [9].
-
DETECTIVE Phase 3 (TAF112582 part 2): a multicentre, phase 3 pivotal, double-blind, double-dummy, randomized placebo-controlled clinical trial of single-dose tafenoquine 300 mg plus standard 3-day chloroquine versus placebo plus standard 3-day chloroquine or primaquine 15 mg for 14 days plus standard 3-day chloroquine [10].
-
GATHER (TAF116564): a multicentre, phase 3 supportive, double-blind, double-dummy, parallel group, randomized trial of single-dose tafenoquine 300 mg plus standard 3-day chloroquine versus primaquine 15 mg for 14 days plus standard 3-day chloroquine [11].
Tafenoquine/chloroquine dose ranging
Adverse event, n (%) | TQ + CQ | PQ + CQ (N = 50) | Placebo + CQ (N = 54) | |||
---|---|---|---|---|---|---|
50 mg (N = 55) | 100 mg (N = 57) | 300 mg (N = 57) | 600 mg (N = 56) | |||
Any nervous system disorder | 17 (31) | 17 (30) | 13 (23) | 16 (29) | 17 (34) | 21 (39) |
Headache | 14 (25) | 17 (30) | 10 (18) | 16 (29) | 14 (28) | 20 (37) |
Dizziness | 7 (13) | 2 (4) | 5 (9) | 4 (7) | 5 (10) | 5 (9) |
Migraine | 0 | 0 | 0 | 0 | 0 | 1 (2) |
Tremor | 0 | 0 | 1 (2) | 1 (2) | 0 | 0 |
Paraesthesia | 0 | 0 | 0 | 1 (2) | 0 | 0 |
Sciatica | 0 | 1 (2) | 0 | 0 | 0 | 0 |
Burning sensation | 1 (2) | 0 | 0 | 0 | 0 | 0 |
Syncope | 0 | 0 | 0 | 0 | 1 (2) | 0 |
Dysaesthesia | 0 | 0 | 0 | 0 | 1 (2) | 0 |
Any psychiatric disorder | 2 (4) | 3 (5) | 5 (9) | 3 (5) | 1 (2) | 1 (2) |
Insomnia | 2 (4) | 3 (5) | 5 (9) | 3 (5) | 3 (6) | 1 (2) |
Tic | 0 | 0 | 0 | 1 (2) | 0 | 0 |
Expanded termsa | ||||||
Asthenia | 5 (9) | 4 (7) | 1 (2) | 5 (9) | 0 | 0 |
Fatigue | 0 | 1 (2) | 1 (2) | 0 | 0 | 0 |
Tafenoquine/chloroquine versus placebo/chloroquine
Tafenoquine/chloroquine versus primaquine/chloroquine
Event—n (%) patients | Gradea | Integrated safety summary | |
---|---|---|---|
Tafenoquine (N = 483) | Primaquine (N = 264) | ||
Nervous system disorders | Any | 105 (22) | 60 (23) |
Grade 1 | 78 (16) | 38 (14) | |
Grade 2 | 26 (5) | 19 (7) | |
Grade 3 | 0 | 2 (< 1) | |
NA | 1 (< 1) | 1 (< 1) | |
Headache | Any | 64 (13) | 40 (15) |
Grade 1 | 45 (9) | 22 (8) | |
Grade 2 | 18 (4) | 16 (6) | |
Grade 3 | 0 | 2 (< 1) | |
NA | 1 (< 1) | 0 | |
Dizziness | Any | 59 (12) | 30 (11) |
Grade 1 | 52 (11) | 25 (9) | |
Grade 2 | 7 (1) | 4 (2) | |
NA | 0 | 1 (< 1) | |
Migraine | Any | 3 (< 1) | 1 (< 1) |
Grade 1 | 2 (< 1) | 0 | |
Grade 2 | 1 (< 1) | 1 (< 1) | |
Syncope | Any | 2 (< 1) | 1 (< 1) |
Grade 1 | 1 (< 1) | 1 (< 1) | |
Grade 2 | 1 (< 1) | 0 | |
Balance disorder | Any | 1 (< 1) | 0 |
Grade 2 | 1 (< 1) | 0 | |
Somnolence | Any | 1 (< 1) | 0 |
Grade 2 | 1 (< 1) | 0 | |
Tremor | Any | 1 (< 1) | 1 (< 1) |
Grade 1 | 1 (< 1) | 1 (< 1) | |
Burning sensation | Any | 0 | 1 (< 1) |
Grade 1 | 0 | 1 (< 1) | |
Dysaesthesia | Any | 0 | 1 (< 1) |
Grade 1 | 0 | 1 (< 1) | |
Hypoaesthesia | Any | 0 | 1 (< 1) |
Grade 2 | 0 | 1 (< 1) | |
Psychiatric disorders | Any | 15 (3) | 12 (5) |
Grade 1 | 9 (2) | 7 (3) | |
Grade 2 | 6 (1) | 5 (2) | |
Insomnia | Any | 15 (3) | 8 (3) |
Grade 1 | 9 (2) | 4 (2) | |
Grade 2 | 6 (1) | 4 (2) | |
Anxiety | Any | 2 (< 1) | 3 (1) |
Grade 1 | 0 | 2 (< 1) | |
Grade 2 | 2 (< 1) | 1 (< 1) | |
Depression | Any | 0 | 1 (< 1) |
Grade 1 | 0 | 1 (< 1) | |
Expanded definition of NPAEs | |||
Asthenia | Any | 8 (2) | 5 (2) |
Grade 1 | 7 (1) | 2 (< 1) | |
Grade 2 | 1 (< 1) | 3 (1) | |
Fatigue | Any | 3 (< 1) | 0 |
Grade 1 | 3 (< 1) | 0 | |
Labyrinthitis | Any | 2 (< 1) | 0 |
Grade 1 | 2 (< 1) | 0 | |
Alcohol intolerance | Any | 1 (< 1) | 0 |
Grade 1 | 1 (< 1) | 0 | |
Vertigo | Any | 3 (< 1) | 1 (< 1) |
Grade 1 | 2 (< 1) | 1 (< 1) | |
Grade 2 | 1 (< 1) | 0 | |
Vestibular disorder | Any | 1 (< 1) | 0 |
Grade 1 | 1 (< 1) | 0 |
Tafenoquine safety database analysis
Adverse event, n (%) | All placeboa (N = 794) | Total TQ 300 mg ≤ 3 days (N = 807) | Total TQ > 300 mg ≤ 3 days (N = 1482) | Total TQ > 300 mg > 3 days (N = 1445) | All TQb (N = 4129) |
---|---|---|---|---|---|
Any nervous system disorder | 170 (21) | 142 (18) | 240 (16) | 269 (19) | 734 (18) |
Headache | 149 (19) | 98 (12) | 164 (11) | 211 (15) | 544 (13) |
Migraine | 4 (< 1) | 3 (< 1) | 0 | 3 (< 1) | 8 (< 1) |
Sinus headache | 1 (< 1) | 0 | 0 | 4 (< 1) | 4 (< 1) |
Tension headache | 0 | 0 | 0 | 2 (< 1) | 2 (< 1) |
Head discomfort | 0 | 0 | 1 (< 1) | 0 | 1 (< 1) |
Visual field defect | 0 | 0 | 0 | 1 (< 1) | 1 (< 1) |
Lethargy | 0 | 0 | 28 (2) | 28 (2) | 56 (1) |
Somnolence | 1 (< 1) | 3 (< 1) | 21 (1) | 1 (< 1) | 25 (< 1) |
Amnesia | 0 | 0 | 0 | 1 (< 1) | 1 (< 1) |
Depressed level of consciousness | 0 | 1 (< 1) | 0 | 0 | 1 (< 1) |
Disturbance in attention | 0 | 0 | 1 (< 1) | 0 | 1 (< 1) |
Dysgeusia | 1 (< 1) | 0 | 17 (1) | 1 (< 1) | 18 (< 1) |
Paraesthesia | 0 | 0 | 3 (< 1) | 4 (< 1) | 8 (< 1) |
Hypoaesthesia | 1 (< 1) | 0 | 3 (< 1) | 1 (< 1) | 4 (< 1) |
Hyperaesthesia | 0 | 0 | 0 | 1 (< 1) | 2 (< 1) |
Burning sensation | 0 | 0 | 0 | 0 | 1 (< 1) |
Coordination abnormal | 0 | 0 | 0 | 2 (< 1) | 2 (< 1) |
Balance disorder | 0 | 1 (< 1) | 0 | 0 | 1 (< 1) |
Dizziness | 24 (3) | 62 (8) | 56 (4) | 33 (2) | 171 (4) |
Syncope | 0 | 2 (< 1) | 1 (< 1) | 2 (< 1) | 5 (< 1) |
Presyncope | 0 | 0 | 0 | 1 (< 1) | 1 (< 1) |
Dizziness postural | 1 (< 1) | 0 | 0 | 0 | 0 |
Loss of consciousness | 1 (< 1) | 0 | 0 | 0 | 0 |
Tremor | 0 | 1 (< 1) | 1 (< 1) | 2 (< 1) | 4 (< 1) |
Muscle contractions involuntary | 0 | 0 | 1 (< 1) | 0 | 1 (< 1) |
Sciatica | 0 | 0 | 0 | 2 (< 1) | 3 (< 1) |
Post herpetic neuralgia | 0 | 0 | 1 (< 1) | 1 (< 1) | 2 (< 1) |
Trigeminal neuralgia | 0 | 0 | 0 | 1 (< 1) | 1 (< 1) |
Any psychiatric disorder | 8 (1) | 16 (2) | 19 (1) | 37 (3) | 79 (2) |
Insomnia | 8 (1) | 15 (2) | 12 (< 1) | 15 (1) | 48 (1) |
Abnormal dreams | 0 | 1 (< 1) | 0 | 6 (< 1) | 7 (< 1) |
Sleep disorder | 0 | 0 | 0 | 3 (< 1) | 3 (< 1) |
Nightmare | 0 | 0 | 0 | 2 (< 1) | 2 (< 1) |
Agitation | 0 | 0 | 0 | 2 (< 1) | 2 (< 1) |
Anxiety | 0 | 2 (< 1) | 0 | 0 | 2 (< 1) |
Anxiety disorder | 0 | 0 | 0 | 2 (< 1) | 2 (< 1) |
Irritability | 0 | 0 | 1 (< 1) | 0 | 2 (< 1) |
Neurosis | 0 | 0 | 0 | 1 (< 1) | 1 (< 1) |
Panic attack | 0 | 0 | 0 | 1 (< 1) | 1 (< 1) |
Psychotic disorder | 0 | 0 | 1 (< 1) | 0 | 1 (< 1) |
Stress | 0 | 0 | 0 | 1 (< 1) | 1 (< 1) |
Euphoric mood | 0 | 0 | 1 (< 1) | 2 (< 1) | 3 (< 1) |
Depressed mood | 0 | 0 | 1 (< 1) | 1 (< 1) | 2 (< 1) |
Depression | 0 | 0 | 0 | 2 (< 1) | 2 (< 1) |
Bipolar disorder | 0 | 0 | 0 | 1 (< 1) | 1 (< 1) |
Disinhibition | 0 | 0 | 1 (< 1) | 0 | 1 (< 1) |
Mood altered | 0 | 0 | 1 (< 1) | 0 | 1 (< 1) |
Alcoholic hangover | 0 | 0 | 0 | 1 (< 1) | 1 (< 1) |
Tic | 0 | 0 | 1 (< 1) | 0 | 1 (< 1) |
Study identification (indication) [refs.] | Study design | Dose | Event preferred term (severity or verbatim terms) | Onset | Duration | Resolution | Relationship to study drug by the Investigator | Intervention/action taken | Medical history |
---|---|---|---|---|---|---|---|---|---|
SB252263/043 (prophylaxis) [89] | R, DB, PC | 750 mg cumulative | Suicidal behaviour (associated with alcohol intoxication)a | Day 8 | 1 day after tafenoquine discontinued | Resolved | Related (chloroquine co-suspect)b | Hospitalized and required corrective therapy (intervention unknown)/withdrawn due to unstable mental state | Family reported history of marital difficulties and previous suicide threat; no other relevant history or concomitant medications reported at screening |
SB252263/050 subject A (volunteers) [90] | R, DB, PC | 350 mg single dose | Acute psychotic episode (severe) | Day 24 | 25 days | Recovered | Possibly related | Hospitalized following progressive emotional distress | Two previous episodes of psychosis (not disclosed at screening) |
SB252263/050 subject B (volunteers) [90] | R, DB, PC | 500 mg single dose | Psychotic episode (severe) | Day 8 | 9 days | Recovered | Remotely related | Hospitalized for a pre-scheduled psychiatric admission | Recent diagnosis of schizophrenia (not disclosed at screening) |
SB252263/014 (volunteers) [unpublished] | R, O, PG | 1200 mg cumulative | Paranoid hallucinotic psychosis (serious) | Day 27 | 3 days | Not resolved | Unrelated | Hospitalized and treated with olanzapine and lorazepam/none | History of “hallucinotic psychosis” 6 months earlier (not disclosed at screening); no obvious signs of psychosis at screening; negative drug screen |
TAF112582 part 1 (P. vivax relapse prevention) [9] | R, DB, PC | 600 mg single dose | Depressed mood | Day 6 | Unknown | Resolved | Unrelated (chloroquine co-suspect)b | Hospitalized (on day 88 for 2 days) with nausea, epigastric pain, diarrhoea, and depression; treated with fluoxetine; consulted with psychiatric specialist (findings unknown) | History of depression but no suicidal tendencies; irregular psychiatric consults; frequent but irregular use of diazepam (10 mg) |
TAF114582 (volunteers) [91] | R, SB, PC, AC | 600 mg single dose | Depressed mood (mild) | Day 4 | 3 days | Resolved | Related | None | No relevant past medical history or concomitant medications were reported; at the time of the event, subject also reported abdominal pain, diarrhoea, and palpitations |
SB252263/033 (prophylaxis) [7] | R, DB, AC | 1200 mg cumulative | Depression (moderate) | Day 24 | 87 days | Resolved | Related | Required corrective therapy (paroxetin)/withdrawn from study | Closed head injury 3 years prior to study |
SB252263/057 subject B (volunteers) [92] | R, DB, PC | 1600 mg cumulative | Depressed mood (mild) | Day 37 | 15 days | Resolved | Unlikely related | None | No relevant past history; treated for a UTI with sulfamethoxazole starting on day 13 (co-suspect) |
SB252263/057 subject A (volunteers) [92] | R, DB, PC | 5200 mgc cumulative | Bipolar depression (mild); depression (mild) | Day 223 (62 days since last dose) | Lost to follow-up | Unknown | Unlikely related | Bupropion and lithium started on study day 223 (ongoing)/excluded due to a positive hepatitis/HIV screen | No relevant past history or concomitant medications |